New MS Treatment Shows Promise in Trial
The drug ublituximab beat a standard oral medication for MS in reducing patients' relapses and proved better at preventing areas of inflammatory damage in the brain.
Landwebs
0
1
The drug ublituximab beat a standard oral medication for MS in reducing patients' relapses and proved better at preventing areas of inflammatory damage in the brain.
